Financing
CuraVac continuously works at improving the treatment of patients with chronic autoimmune diseases.
At CuraVac we believe in treating diseases, not in maintenance therapy. We want to treat the patients forever and not forever treat the patients.
The therapeutic vaccine technique that is now being tested to cure or greatly ameliorate myasthenia gravis patients with only 3 vaccine injections is a technology platform that can work for many other debilitating chronic autoimmune diseases.
So far we raised more than €18 million to reach the common goal of our Grantors, Investors and Donators of a world without MG and other autoimmune diseases.
We rely on the three natural sources of financing to reach our goal of a world without autoimmune diseases:
Grants, Investments and Donations.
